Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

For further information, see CMDT Part 29-20: Vitamin E Deficiency

Key Features

  • Most commonly results from

    • Severe malabsorption (eg, cystic fibrosis)

    • Abetalipoproteinemia (genetic disorder)

    • Chronic cholestatic liver disease (including biliary atresia)

Clinical Findings

  • Areflexia

  • Disturbances of gait

  • Decreased vibration and proprioception

  • Ophthalmoplegia


  • Plasma vitamin E level below normal range of 0.5–0.7 mg/dL


  • Vitamin E supplementation, although optimum therapeutic dose has not been defined

  • Large doses, often administered parenterally, can be used to improve the neurologic complications seen in abetalipoproteinemia and cholestatic liver disease

  • Several trials of supplemental vitamin E have shown slower cognitive decline in patients with Alzheimer disease

  • Vitamin E supplementation may also provide benefit in patients with nonalcoholic fatty liver disease

  • Supplemental vitamin E has no benefit in preventing cardiovascular disease or cancer

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.